WillItSurvive
Pharma and healthcare groups · United States

Merck

merck.com ↗

Merck is a $65B global pharma giant built on Keytruda, vaccines, and a broad prescription drug pipeline.

Defensible for now
Assessed 20 July 2026 · Evidence as of 20 July 2026
Real protection, with named pressure against it.
On the recordSince 20 July 2026 · Checkable from Aug. 4, 2026 · Every call on the record Checkpoint: Q2 2026 earnings call, watch Qlex conversion, Winrevair, Ohtuvayre, Gardasil trends
The call

Merck's size and patents hold for now, but nearly half its revenue rides on one drug facing patent expiry, government pricing, and biosimilar litigation by 2028.

Merck makes prescription drugs and sells them to hospitals, doctors, and patients worldwide. Its biggest earner, a cancer drug called Keytruda, loses patent protection in 2028, meaning cheaper copycat versions can enter the market. The U.S. government is also starting to negotiate drug prices directly (beginning late 2025), which will cut into profits. Merck has new drugs in development and is trying to switch Keytruda to a longer-acting version to extend its sales life, but whether those moves work fast enough before revenue drops is the key question that will determine if investors make or lose money over the next few years.

Why
01
AI pressure: AI-driven drug discovery labs (Isomorphic Labs, Recursion Pharmaceuticals). AI-accelerated discovery could help rivals design next-gen immunotherapies or biosimilars faster than Merck's Qlex transition completes. Could AI do the core job? Unlikely.
02
Bigger players: U.S. government (Medicare IRA price negotiation, TrumpRx pricing deal). Direct federal price-setting on Keytruda starts 2029, and the Dec. 2025 TrumpRx deal already sets a new pricing floor across products. Could a giant copy it? No, they are blocked.
03
What protects it. Patent estate, FDA approvals, manufacturing scale, and payer relationships across a diversified drug and vaccine portfolio.
What would change this call
Merck reports Keytruda Qlex subcutaneous conversion rate in 2026-2027 earnings calls. Shows whether patients are shifting off IV Keytruda ahead of the 2028 patent cliff as planned.
Biosimilar patent litigation against Keytruda filed or resolved in 2026-2027. Signals how soon low-cost generic competitors can enter after 2028.
Gardasil sales trend in China and Japan through 2026 earnings reports. Shows whether the 39% 2025 decline stabilizes or continues worsening.
Key numbers
  • FY2025 revenue: $65.0B, up 1% nominal (2025-12-31)
  • Keytruda: $31.7B, 49% of total revenue (2025-12-31)
  • Gardasil sales fell 39% to $5.2B (2025-12-31)
Named risks
  • Keytruda 2028 patent cliff threatens ~49% of total revenue. Severity: high
  • IRA Medicare price negotiation on Keytruda effective Jan 1 2029. Severity: high
  • MFN/TrumpRx pricing regime could expand and compress U.S. revenue further. Severity: medium
  • Gardasil decline in China and Japan continuing to erode vaccine revenue. Severity: medium
  • Unproven M&A integration (Cidara, Terns, Verona) to replace Keytruda revenue at scale. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Bristol Myers SquibbcontestingOpdivo competes head-to-head with Keytruda in oncology as of 2026
Eli Lillylosing toLilly's ~$65.2B 2025 revenue and GLP-1 dominance make it the fastest-growing large-cap peer
Johnson & Johnsonlosing toJ&J leads global pharma revenue at ~$94.2 billion in 2025 versus Merck's $65.0 billion
AstraZenecacontestingImfinzi and Enhertu compete in oncology against Keytruda as of 2026
Biosimilar makersgaining onBPCIA patent litigation on Keytruda expected to begin as early as 2026 ahead of 2028 cliff
Questions people ask
Is Merck profitable in 2026?
Merck posted a Q1 2026 GAAP net loss due to a $9.0 billion non-cash R&D charge tied to the Cidara acquisition, but underlying operations remain profitable; FY2026 guidance calls for non-GAAP EPS of $5.04-$5.16 on sales of $65.8-$67.0 billion, as of March 31, 2026.
Could AI replace Merck?
No. AI cannot approve, manufacture, or distribute drugs. Merck's revenue is protected by FDA-approved labels, over 100 issued Keytruda patents, and manufacturing/distribution scale. Merck uses AI as a discovery tailwind, including an up-to-$1 billion Google Cloud Gemini deal announced April 22, 2026.
What happens to Merck when Keytruda's patent expires?
Keytruda's core U.S. patent is expected to expire in 2028; it generated $31.7 billion in 2025, about 49% of Merck's revenue. Merck's mitigation is the subcutaneous Keytruda Qlex (approved Sept 19, 2025), which the CEO says could capture 30-40% of the U.S. patient base.
Is Merck laying off employees in 2026?
No broad layoffs are evident. Merck reported roughly 75,000 employees as of Dec 31, 2025, flat versus 2024, while third-party data (Revelio Labs) shows active job postings up 17.7% in 2025 to 3,418, suggesting continued hiring despite flat headcount.
Who is Merck's biggest competitor?
In oncology, Bristol Myers Squibb's Opdivo competes head-to-head with Keytruda. Other major peers include Pfizer, AstraZeneca, AbbVie, and Eli Lilly; Johnson & Johnson leads the broader pharma sector at roughly $94.2 billion in 2025 revenue versus Merck's $65.0 billion.
Is Merck the same company as Merck KGaA in Germany?
No. Merck & Co. (Rahway, NJ, ticker MRK) and Merck KGaA (Darmstadt, Germany) split permanently in 1917 after U.S. expropriation and are legally distinct, unrelated companies still in trademark litigation over the 'Merck' name, per Wikipedia as of 2026-07-20.
Timeline
  • 2026-06-05Merck settles bulk of Gardasil product-liability litigation for a reported ~$50 million
  • 2026-05-05Merck completes ~$6.7 billion acquisition of Terns Pharmaceuticals (TERN-701, CML candidate)
  • 2026-04-22Merck and Google Cloud announce up-to-$1 billion agentic AI partnership using Gemini Enterprise
  • 2026-03-31Q1 2026 revenue hits $16.29 billion, up 5% YoY, beating consensus
  • 2026-03-25Merck announces ~$6.7 billion Terns Pharmaceuticals acquisition
  • 2026-01-07Merck completes ~$9.2 billion Cidara Therapeutics acquisition (antiviral CD388)
  • 2025-12-19Merck reaches MFN pricing deal with Trump administration, cuts Januvia price via TrumpRx.gov
  • 2025-11Merck announces ~$9.2 billion Cidara Therapeutics acquisition
  • 2025-10-07Merck closes acquisition of Verona Pharma, adding COPD drug Ohtuvayre
  • 2025-09-19FDA approves Keytruda Qlex, subcutaneous pembrolizumab, for solid-tumor indications
Revision history
20 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources